申请人:ALLERGAN SALES, INC.
公开号:US20020161051A1
公开(公告)日:2002-10-31
Compounds of formula (i) and of formula (ii)
1
wherein the symbols have the meaning disclosed in the specification, specifically or selectively modulate &agr;
2B
and/or &agr;
2C
adrenergic receptors in preference over &agr;
2A
adrenergic receptors, and as such are useful for alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity.
式(i)和式(ii)的化合物
其中符号的含义在说明书中披露,特别或选择性地调节&agr;
2B
和/或&agr;
2C
肾上腺素受体,优先于&agr;
2A
肾上腺素受体,因此对缓解慢性疼痛和触痛有用,并且几乎没有或只有极小的心血管和/或镇静活性。